BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis, and biological evaluation of pyrrolobenzodiazepine-containing hypoxia-activated prodrugs. 2017

Peter S Dragovich, and Fabio Broccatelli, and Jinhua Chen, and Peter Fan, and Hoa Le, and Weiguang Mao, and Thomas H Pillow, and Andrew G Polson, and John Wai, and Zijin Xu, and Hui Yao, and Donglu Zhang
Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA. Electronic address: dragovich.peter@gene.com.

The ability of various pyrrolobenzodiazepine(PBD)-containing cytotoxic compounds to function as hypoxia-activated prodrugs was assessed. These molecules incorporated a 1-methyl-2-nitro-1H-imidazole hypoxia-activated trigger (present in the clinically evaluated compound TH-302) in a manner that masked a reactive imine moiety required for cytotoxic activity. Incubation of the prodrugs with cytochrome P450-reductase under normoxic and hypoxic conditions revealed that some, but not all, were efficient substrates for the enzyme. In these experiments, prodrugs derived from PBD-monomers underwent rapid conversion to the parent cytotoxic compounds under low-oxygen conditions while related PBD-dimers did not. The ability of a given prodrug to function as an efficient cytochrome P450-reductase substrate correlated with the ratio of cytotoxic potencies measured for the compound against NCI460 cells under normoxic and hypoxic conditions.

UI MeSH Term Description Entries
D009251 NADPH-Ferrihemoprotein Reductase A flavoprotein that catalyzes the reduction of heme-thiolate-dependent monooxygenases and is part of the microsomal hydroxylating system. EC 1.6.2.4. Cytochrome P-450 Reductase,Ferrihemoprotein P-450 Reductase,NADPH Cytochrome P-450 Oxidoreductase,NADPH Cytochrome P-450 Reductase,NADPH Cytochrome c Reductase,Cytochrome P-450 Oxidase,Cytochrome P450 Reductase,Ferrihemoprotein P450 Reductase,NADPH Cytochrome P450 Oxidoreductase,NADPH Cytochrome P450 Reductase,NADPH-Cytochrome P450 Reductase,NADPH-P450 Reductase,Cytochrome P 450 Oxidase,Cytochrome P 450 Reductase,Ferrihemoprotein P 450 Reductase,NADPH Cytochrome P 450 Oxidoreductase,NADPH Cytochrome P 450 Reductase,NADPH Ferrihemoprotein Reductase,NADPH P450 Reductase,Oxidase, Cytochrome P-450,P-450 Oxidase, Cytochrome,P450 Reductase, Cytochrome,P450 Reductase, NADPH-Cytochrome,Reductase, Cytochrome P-450,Reductase, Cytochrome P450,Reductase, Ferrihemoprotein P-450,Reductase, Ferrihemoprotein P450,Reductase, NADPH-Cytochrome P450,Reductase, NADPH-Ferrihemoprotein,Reductase, NADPH-P450
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D011758 Pyrroles Azoles of one NITROGEN and two double bonds that have aromatic chemical properties. Pyrrole
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000860 Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms. Anoxia,Oxygen Deficiency,Anoxemia,Deficiency, Oxygen,Hypoxemia,Deficiencies, Oxygen,Oxygen Deficiencies
D001569 Benzodiazepines A group of two-ring heterocyclic compounds consisting of a benzene ring fused to a diazepine ring. Benzodiazepine,Benzodiazepine Compounds
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs

Related Publications

Peter S Dragovich, and Fabio Broccatelli, and Jinhua Chen, and Peter Fan, and Hoa Le, and Weiguang Mao, and Thomas H Pillow, and Andrew G Polson, and John Wai, and Zijin Xu, and Hui Yao, and Donglu Zhang
Design, synthesis and evaluation of molecularly targeted hypoxia-activated prodrugs.
April 2016, Nature protocols,
Peter S Dragovich, and Fabio Broccatelli, and Jinhua Chen, and Peter Fan, and Hoa Le, and Weiguang Mao, and Thomas H Pillow, and Andrew G Polson, and John Wai, and Zijin Xu, and Hui Yao, and Donglu Zhang
Synthesis and biological evaluation of hypoxia-activated prodrugs of SN-38.
May 2017, European journal of medicinal chemistry,
Peter S Dragovich, and Fabio Broccatelli, and Jinhua Chen, and Peter Fan, and Hoa Le, and Weiguang Mao, and Thomas H Pillow, and Andrew G Polson, and John Wai, and Zijin Xu, and Hui Yao, and Donglu Zhang
Design, synthesis and evaluation of targeted hypoxia-activated prodrugs applied to chondrosarcoma chemotherapy.
May 2020, Bioorganic chemistry,
Peter S Dragovich, and Fabio Broccatelli, and Jinhua Chen, and Peter Fan, and Hoa Le, and Weiguang Mao, and Thomas H Pillow, and Andrew G Polson, and John Wai, and Zijin Xu, and Hui Yao, and Donglu Zhang
Design and synthesis of novel pyrrolobenzodiazepine (PBD) prodrugs for ADEPT and GDEPT.
September 2000, Bioorganic & medicinal chemistry letters,
Peter S Dragovich, and Fabio Broccatelli, and Jinhua Chen, and Peter Fan, and Hoa Le, and Weiguang Mao, and Thomas H Pillow, and Andrew G Polson, and John Wai, and Zijin Xu, and Hui Yao, and Donglu Zhang
Dendrimer-based prodrugs: design, synthesis, screening and biological evaluation.
June 2007, Combinatorial chemistry & high throughput screening,
Peter S Dragovich, and Fabio Broccatelli, and Jinhua Chen, and Peter Fan, and Hoa Le, and Weiguang Mao, and Thomas H Pillow, and Andrew G Polson, and John Wai, and Zijin Xu, and Hui Yao, and Donglu Zhang
Carbapenem-based prodrugs. Design, synthesis, and biological evaluation of carbapenems.
April 2005, European journal of medicinal chemistry,
Peter S Dragovich, and Fabio Broccatelli, and Jinhua Chen, and Peter Fan, and Hoa Le, and Weiguang Mao, and Thomas H Pillow, and Andrew G Polson, and John Wai, and Zijin Xu, and Hui Yao, and Donglu Zhang
Hypoxia Activated Prodrugs: Factors Influencing Design and Development.
January 2015, Current medicinal chemistry,
Peter S Dragovich, and Fabio Broccatelli, and Jinhua Chen, and Peter Fan, and Hoa Le, and Weiguang Mao, and Thomas H Pillow, and Andrew G Polson, and John Wai, and Zijin Xu, and Hui Yao, and Donglu Zhang
Design, Synthesis and In-Vitro Biological Evaluation of Antofine and Tylophorine Prodrugs as Hypoxia-Targeted Anticancer Agents.
June 2021, Molecules (Basel, Switzerland),
Peter S Dragovich, and Fabio Broccatelli, and Jinhua Chen, and Peter Fan, and Hoa Le, and Weiguang Mao, and Thomas H Pillow, and Andrew G Polson, and John Wai, and Zijin Xu, and Hui Yao, and Donglu Zhang
Design, synthesis and biological evaluation of novel tumor hypoxia-activated EGFR tyrosine kinase inhibitors.
December 2022, Bioorganic chemistry,
Peter S Dragovich, and Fabio Broccatelli, and Jinhua Chen, and Peter Fan, and Hoa Le, and Weiguang Mao, and Thomas H Pillow, and Andrew G Polson, and John Wai, and Zijin Xu, and Hui Yao, and Donglu Zhang
Bioreduction activated prodrugs of camptothecin: molecular design, synthesis, activation mechanism and hypoxia selective cytotoxicity.
May 2005, Organic & biomolecular chemistry,
Copied contents to your clipboard!